Periodontitis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook
2020 Periodontitis PIPELINE HIGHLIGHTS
Periodontitis is one of the widely researched conditions during 2020 with 13 companies actively focusing on realizing pipeline’s potential. Development of Periodontitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Periodontitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Periodontitis.
Good progress is anticipated during 2020 and 2021 with Periodontitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Periodontitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Periodontitis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Periodontitis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Periodontitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Periodontitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Periodontitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Periodontitis DRUG PROFILES
Periodontitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
Both small size and large size pharmaceutical companies are investing their resources in Periodontitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Periodontitis. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 13 Periodontitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Periodontitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Amyndas Pharmaceuticals LLC, Cellatoz Therapeutics Inc, Cells for Cells SA, Denteric Pty Ltd, Geistlich Pharma AG, GlycoMira Therapeutics Inc, Guangzhou Saliai Stem cell Science and Technology Co Ltd , KIMS Pharmaceutical Co Ltd, MetiMedi Pharmaceuticals Co Ltd, Noveome Biotherapeutics Inc, PerioTrap Pharmaceuticals GmbH, TGV Laboratories Inc, Vaxcyte
REASONS TO BUY
Periodontitis is one of the widely researched conditions during 2020 with 13 companies actively focusing on realizing pipeline’s potential. Development of Periodontitis medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Periodontitis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Periodontitis.
Good progress is anticipated during 2020 and 2021 with Periodontitis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Periodontitis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Periodontitis DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Periodontitis pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Periodontitis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Periodontitis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Periodontitis pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Periodontitis DRUG PROFILES
Periodontitis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
- Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
- Phase of development
- Mechanism of Action
- Route of Administration
- Companies involved including originator, licensing companies, developer, investors, and others
- New molecular entity details
- Orphan drug designation and other special status provided by regulators
Both small size and large size pharmaceutical companies are investing their resources in Periodontitis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Periodontitis. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 13 Periodontitis companies including company overview, key snapshot, contact information, and their strategies on accelerating Periodontitis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Companies analyzed in the report include- Amyndas Pharmaceuticals LLC, Cellatoz Therapeutics Inc, Cells for Cells SA, Denteric Pty Ltd, Geistlich Pharma AG, GlycoMira Therapeutics Inc, Guangzhou Saliai Stem cell Science and Technology Co Ltd , KIMS Pharmaceutical Co Ltd, MetiMedi Pharmaceuticals Co Ltd, Noveome Biotherapeutics Inc, PerioTrap Pharmaceuticals GmbH, TGV Laboratories Inc, Vaxcyte
REASONS TO BUY
- The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
- This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
- Buyers can identify most promising drug candidates for treatment of Periodontitis
- It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
- Users can estimate possible delays in the delivery of pipeline or launch of new products
- Stay ahead of competition through understanding their pipeline progression, strategies and outlook
- The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
- Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO PERIODONTITIS
1.1 Periodontitis- Disease overview
1.2 Periodontitis- Market Size
1.3 Periodontitis- Companies Involved
2. PERIODONTITIS PIPELINE SNAPSHOT- 2020
2.1 Periodontitis Pipeline by Phase
2.2 Periodontitis Pipeline by Mechanism of Action
2.3 Periodontitis Pipeline by Route of Administration
2.4 Periodontitis Pipeline- New Molecular Entities
2.5 Periodontitis Pipeline- Orphan Drug Designation/ Special Designation
3. PERIODONTITIS DRUG PROFILES
3.1 Current Status
3.2 Periodontitis Drug Snapshot
3.3 Periodontitis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Amyndas Pharmaceuticals LLC Periodontitis Pipeline Insights and Clinical Trials
4.2 Cellatoz Therapeutics Inc Periodontitis Pipeline Insights and Clinical Trials
4.3 Cells for Cells SA Periodontitis Pipeline Insights and Clinical Trials
4.4 Denteric Pty Ltd Periodontitis Pipeline Insights and Clinical Trials
4.5 Geistlich Pharma AG Periodontitis Pipeline Insights and Clinical Trials
4.6 GlycoMira Therapeutics Inc Periodontitis Pipeline Insights and Clinical Trials
4.7 Guangzhou Saliai Stem cell Science and Technology Co Ltd Periodontitis Pipeline Insights and Clinical Trials
4.8 KIMS Pharmaceutical Co Ltd Periodontitis Pipeline Insights and Clinical Trials
4.9 MetiMedi Pharmaceuticals Co Ltd Periodontitis Pipeline Insights and Clinical Trials
4.10 Noveome Biotherapeutics Inc Periodontitis Pipeline Insights and Clinical Trials
4.11 PerioTrap Pharmaceuticals GmbH Periodontitis Pipeline Insights and Clinical Trials
4.12 TGV Laboratories Inc Periodontitis Pipeline Insights and Clinical Trials
4.13 Vaxcyte Periodontitis Pipeline Insights and Clinical Trials
5. PERIODONTITIS MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
1.1 Periodontitis- Disease overview
1.2 Periodontitis- Market Size
1.3 Periodontitis- Companies Involved
2. PERIODONTITIS PIPELINE SNAPSHOT- 2020
2.1 Periodontitis Pipeline by Phase
2.2 Periodontitis Pipeline by Mechanism of Action
2.3 Periodontitis Pipeline by Route of Administration
2.4 Periodontitis Pipeline- New Molecular Entities
2.5 Periodontitis Pipeline- Orphan Drug Designation/ Special Designation
3. PERIODONTITIS DRUG PROFILES
3.1 Current Status
3.2 Periodontitis Drug Snapshot
3.3 Periodontitis Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Amyndas Pharmaceuticals LLC Periodontitis Pipeline Insights and Clinical Trials
4.2 Cellatoz Therapeutics Inc Periodontitis Pipeline Insights and Clinical Trials
4.3 Cells for Cells SA Periodontitis Pipeline Insights and Clinical Trials
4.4 Denteric Pty Ltd Periodontitis Pipeline Insights and Clinical Trials
4.5 Geistlich Pharma AG Periodontitis Pipeline Insights and Clinical Trials
4.6 GlycoMira Therapeutics Inc Periodontitis Pipeline Insights and Clinical Trials
4.7 Guangzhou Saliai Stem cell Science and Technology Co Ltd Periodontitis Pipeline Insights and Clinical Trials
4.8 KIMS Pharmaceutical Co Ltd Periodontitis Pipeline Insights and Clinical Trials
4.9 MetiMedi Pharmaceuticals Co Ltd Periodontitis Pipeline Insights and Clinical Trials
4.10 Noveome Biotherapeutics Inc Periodontitis Pipeline Insights and Clinical Trials
4.11 PerioTrap Pharmaceuticals GmbH Periodontitis Pipeline Insights and Clinical Trials
4.12 TGV Laboratories Inc Periodontitis Pipeline Insights and Clinical Trials
4.13 Vaxcyte Periodontitis Pipeline Insights and Clinical Trials
5. PERIODONTITIS MARKET NEWS AND UPDATES
6. APPENDIX
6.1 Sources and Methodology
6.2 Contact Information
